Results 51 to 60 of about 3,554 (229)

Amino acid substitutions in human growth hormone affect secondary structure and receptor binding

PLoS ONE, 2023
The interaction between human Growth Hormone (hGH) and hGH Receptor (hGHR) has basic relevance to cancer and growth disorders, and hGH is the scaffold for Pegvisomant, an anti-acromegaly therapeutic.
Andrei Rajkovic, Sandesh Kanchugal, Eldar Abdurakhmanov, Rebecca Howard, Sebastian Wärmländer, Joseph Erwin, Hugo A. Barrera Saldaña, Astrid Gräslund, Helena Danielson, Samuel Coulbourn Flores   +9 more
doaj   +3 more sources

GH-secreting pituitary macroadenoma (acromegaly) associated with progressive dental malocclusion and refractory CPAP treatment [PDF]

, 2017
Background: A link between progressive dental malocclusion, the use of a continuous positive airway pressure mask and GH-secreting pituitary macroadenoma (acromegaly) has not been previously reported.
Brunet i Llobet, Lluís, Dios-Miranda, David de, Giménez Rubio, Josep Anton, Lahor i Soler, Eduard, Miranda i Rius, Jaume   +4 more
core   +2 more sources

Tumor‐infiltrating immune cells predict the response to somatostatin receptor ligands only in somatotropinomas naïve to medical therapy

Journal of Neuroendocrinology, Volume 37, Issue 11, November 2025.
Abstract Tumor‐infiltrating immune cells (TICs) are important components of the tumor microenvironment (TME). They regulate somatotroph adenoma treatment responses to therapy with somatostatin receptor ligands (SRLs), mediated by soluble factors and cytokines. In this study, we assessed the effect of SRLs treatment on TICs.
Sabrina Chiloiro, Alessandra Vicari, Antonella Giampietro, Pier Paolo Mattogno, Natalia Cappoli, Greis Konini, Rosalinda Calandrelli, Liverana Lauretti, Simona Gaudino, Mario Rigante, Guido Rindi, Alessandro Olivi, Laura De Marinis, Antonio Bianchi, Francesco Doglietto, Marco Gessi, Alfredo Pontecorvi   +16 more
wiley   +1 more source

The role of primary pharmacological therapy in acromegaly [PDF]

, 2014
BACKGROUND AND OBJECTIVES: Primary pharmacological therapy may be the only viable treatment option for many patients with acromegaly, especially those presenting with advanced disease with large inoperable tumors.
Alfredo Adolfo Reza Albarrán, Alin Abreu, Ana Laura Espinosa de los Monteros, Carmen A. Carrasco, Moisés Mercado, Mônica Gadelha   +5 more
core   +1 more source

Real-world comorbidities and treatment patterns of patients with acromegaly in two large US health plan databases [PDF]

, 2012
Acromegaly is a rare, chronic, and debilitating disease that results from excessive growth hormone production. Clinically, this disease is associated with enlargement of soft tissue, excessive skeletal growth, and increased risk of cardiovascular disease.
Elisabeth Le Nestour, Maureen Neary, Tanya Burton, Tim Bancroft   +3 more
core   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

Small, Volume 21, Issue 29, July 24, 2025.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai, Dhwani Rana, Mitali Patel, Neha Bajwa, Rajendra Prasad, Lalitkumar K. Vora   +5 more
wiley   +1 more source

Pasireotide-LAR in acromegaly patients treated with a combination therapy: a real-life study

Endocrine Connections, 2019
Purpose: Little data are available regarding the safety and efficacy of s witching to Pasireotide-LAR monotherapy in acromegaly patients with partial resistance to first-generation somatostatin agonists (1gSRL) who require combination treatment with ...
Hélène Lasolle, Amandine Ferriere, Alexandre Vasiljevic, Sandrine Eimer, Marie-Laure Nunes, Antoine Tabarin   +5 more
doaj   +1 more source

Hypersomatotropism and Hypercortisolism Caused by a Plurihormonal Pituitary Adenoma in a Dog

Journal of Veterinary Internal Medicine, Volume 39, Issue 4, July/August 2025.
ABSTRACT A 12‐year‐old, male Labrador Retriever was presented because of polyuria, polydipsia, polyphagia, joint pain, and physical features consistent with acromegaly. Circulating insulin‐like growth factor‐1 (IGF‐1) concentration was increased (> 1000 ng/mL; reference interval [RI], 42–449), suggestive of hypersomatotropism.
Elber A. Soler Arias, Ricardo Rodas Elvir, Adrian F. Daly, Hans S. Kooistra   +3 more
wiley   +1 more source

Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil [PDF]

, 2011
A acromegalia é uma doença associada à elevada morbidade e à redução da expectativa de vida. Em virtude do seu caráter insidioso e do seu não reconhecimento, o diagnóstico é frequentemente realizado com atraso, o que, associado às complicações ...
ABUCHAM, Julio, ARAUJO, Luiz Antônio de, BOGUSZEWSKI, Cesar L., BRONSTEIN, Marcello D., CZEPIELEWSKI, Mauro, FARIA, Manuel dos S., GADELHA, Mônica R., JALLAD, Raquel S., MUSOLINO, Nina R. de C., NAVES, Luciana A., RIBEIRO-OLIVEIRA JÚNIOR, Antônio, VIEIRA NETO, Leonardo, VILAR, Lucio   +12 more
core   +4 more sources

Pegvisomant: structure and function [PDF]

Journal of Molecular Endocrinology, 2002
Pegvisomant is the pegylated form of mutant growth hormone (B2036). B2036 has increased affinity in one binding site and lowered affinity in its second binding site, it has been shown that this molecule still enables dimerisation of the growth hormone receptor at the cell surface but does not allow the necessary conformational changes for signalling ...
S, Pradhananga, I, Wilkinson, R J M, Ross   +2 more
openaire   +2 more sources